Holy Stone Healthcare (HSHC) has once again won the Innovation award at the 2025 Taipei Biotech Awards. After years of dedicated research and development, HSHC has advanced its targeted, controlled biopolymer drug delivery system into the HylX drug delivery platform, designed to deliver therapeutics across key biological barriers to the brain, eye, and tumors.

The HylX drug delivery platform utilizes modified hyaluronic acid (HA) as a drug carrier with dual mechanisms of conjugation and encapsulation. This enables chemical bonding with therapeutic agents or particle-based encapsulation, improving the solubility and stability of hydrophobic drugs. Based on the natural affinity between HA and cell surface receptors, the agents were efficiently transported across biological barriers, including the blood-brain barrier (BBB), blood-retinal barrier (BRB), and tumor microenvironment (TME). In addition, optimized formulations extend drug retention time in target tissues that can reduce dosage and side effects.

The HylX drug delivery platform is being applied to multiple therapeutic areas, with specialized techniques tailored for different diseases:

• HylNeuro™: Drugs were delivered across the BBB to the cerebral cortex and hippocampus. ND108E has demonstrated Aβ plaques reduction and cognitive improvement in Alzheimer’s Disease animal models, indicating strong therapeutic potential.
• HylRetinX™: Drugs were protected for oral delivery to the retina. AMD112 suppressed retinal neovascularization in Choroidal neovascularization animal models, offering an innovative oral therapy for age-related macular degeneration.
• HylTargis™: Enhances drug penetration into the core of solid tumors. CA102N has completed a Phase I clinical trial, demonstrating safety and preliminary efficacy. When combined with chemotherapy, showed potential to reduce chemotherapy dosage and related side effects.
• HylMusa™: Encapsulates small molecules for sustained or target release, and supporting mucosal healing in the gastrointestinal tract. IBD98-M has completed a Phase IIa clinical trial, confirming reduced drug dosage with effective symptom relief.
• HylCaryo™: Specific design for nucleic acid delivery, enhancing mRNA stability and slowing degradation.

HSHC is currently engaged in strategic discussions with global pharmaceutical partners to expand the applications of the HylX drug delivery platform and to promote its assets into later-stage clinical development, with the goal of providing patients with more innovative treatment options.

HSHC is participating in the BIO International Convention (USBIO 2025) held in Boston from June 16 to June 19, presenting our HylX drug delivery platform and assets. During the event, we engage in partnership discussions with global pharmaceutical companies

Kobe, Japan-May 14. 2025 -Holy Stone Health Care (HSHC) presented its proprietary HylX drug delivery technology platform at the 12th international Symposium of Drug Delivery System (SDDS 2025).